Community-acquired pneumonia

Current Opinion in Pulmonary Medicine

Volumn 4, Issue 3, 1998, Pages 162-172

  Lynch III, Joseph P ^a   Martinez, Fernando J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMORBIDITY; DRUG COMBINATION; HUMAN; INCIDENCE; LUNG MYCOSIS; MICROBIOLOGY; MIDDLE AGED; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE; VIROLOGY; VIRUS PNEUMONIA;

ADULT; AGE DISTRIBUTION; AGED; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DRUG THERAPY, COMBINATION; HUMANS; INCIDENCE; LUNG DISEASES, FUNGAL; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0032060334     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Bartlett JG, Mundy LM: Community-acquired pneumonia. N Engl J Med 1995, 333:1618-1623.
2. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN: Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996, 101:508-515. Prospective study in Nova Scotia of 149 ambulatory adults with CAP. Most were young and had no comorbidity. Only 5% required hospitalization; none died. Serologies for atypical pathogens were routinely performed. Etiological agents identified included M. pneumoniae (26%); C. pneumoniae (14%): L. pneumophilia (0.7%). Clinical or radiographic features were similar among those with atypical or undetermined (presumably typical) etiology. The use of macrolides were no more effective than other antibiotics, even in patients with atypical pathogens.
3. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med 1997, 336:243-250. A prediction rule to predict likelihood of death within 30 days of presentation in adults with CAP was derived. Patients were stratified into five classes based upon risk of death. Criteria of importance in predicting mortality included age, presence or absence of comorbid illness, and specific aberrations on physical examination or laboratory studies. Mortality rates ranged from 0.1% to 0.4% in class I patients (low risk) to greater than 27% for class V (high risk). Such a "prediction rule" may better discriminate patients who are best or worst candidates for outpatient therapy.
4. Marston BJ, Plouffe JF, File TM, Hackman BA, Salstrom SJ, Lipman HB, Kolczak MS, Breiman RF: Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997, 157:1709-1718.
5. Marrie TJ: Community-acquired pneumonia. Clin Infec Dis 1994, 18:501-515.
6. Fein AM, Niederman MS: Guidelines for the initial management of community-acquired pneumonia: savory recipe or cookbook for disaster? Am J Respir Crit Care Med 1995, 152:1149-1153.
7. Niederman MS, Bass JB, Campbell GD, Efin AM: Guidelines for the initial management of community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993, 148:1418-1426.
8. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN: Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1995, 274:134-141.
9. Andriole V: Community-acquired pneumonia requiring hospitalization. Infect Dis Clin Pract 1996, 5:S136-S141.
10. Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R, Singer DE, Coley CM, Marrie TJ, Fine MJ: Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997, 278:32-39.
11. Hirani NA, Macfarlane JT: Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997, 52:17-21.
12. Feldman C: Severe community-acquired pneumonia. Curr Opin Pulm Med 1997, 3:98-104.
13. Huchon G, Woodhead M, ESOCAP Committee: Guidelines for the management of adult community-acquired lower respiratory tract infections: European Study of Community Acquired Pneumonia (ESOCAP) Committee. Eur Respir J 1998, in press.
14. Lieberman D, Schlaeffer F, Boldur I, Lieberman D: Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996, 51:179-184.
15. Neill AM, Martin IR, Weir R, Anderson R, Chereshky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, Chambers ST, Town GI: Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996, 51:1010-1016.
16. File TM, JR, Tan JS: Incidence, etiologic petterns, and diagnostic testing of community-acquired pneumonia. Curr Opin Pulm Med 1997, 3:89-97.
17. Fiore AE, Nuorti JP, Levine OS, Marx A, et al.: Epidemic Legionnaires's disease two decades later: old sources, new diagnostic methods. Clin Infect Dis 1998, 26:426-433.
18. Mundy LM, Auwaerter PG, Oldach D, Warner ML, Burton A, Vance E, Gaydos CA, Joseph JM, Gopalan R, Moore RD, Quinn TC, Charache P, Bartlett JG: Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995, 152:1309-1315.
19. Torres A, Dorca J, Zalacajn R, Bello S: Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996, 154:1456-1461.
20. Wood GM, Johnson BC, McCormack JG: Moraxella catarrhalis: pathogenic significance in respiratory tract infections treated by community practitioners. Clin Infect Dis 1996, 22:632-636.
21. Von Hertzen L, Alakarppa H, Koskinen R, Liippo K, Surcel HM, Leinonen M, Saikku P: Chlamydia pneumonia infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect 1997, 118:155-164.
22. Lieberman D, Lieberman D: Atypical pathogen pneumonia. Curr Opin Pulm Med 1997, 3:111-115.
23. Plouffe JF, Herbert MT, File TM Jr: Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob Agents Chemother 1996, 40:1175-1179.
24. Metlay JP, Schuylz R, Li YH, Singer DE, et al.: Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997, 157:1453-1459.
25. Lieberman D, Lieberman D, Schlaeffer F, Porath A: Community acquired pneumonia in old age: a prospective study of 91 patients from home. Age Aging 1997, 26:69-75.
26. Meehan TP, Fine MJ, Krumholz HM, Scinto JD: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278:2080-2084.
27. Marrie TJ, Blanchard W: A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. J Am Geriatr Soc 1997, 45:50-55.
28. Riquelme R, Torres A, El-Ebiary M, Puig de la Bellacasa J, Estruch R: Community acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996, 154:1450-1455.
29. Troy CJ, Peeling RW, Ellis AG, Hockin JC, Bennett DA, Murphy MR, Spika JS: Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA 1997, 277:1214-1218.
30. Stout JE, Yu VL: Legionellosis. N Engl J Med 1997, 337:682-686.
31. Metlay JP, Fine MJ, Schulz R, Marrie TJ, Coley CM, Kapoor WN, Singer DE: Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997, 12:423-430.
32. Muder RR, Brennen C, Swenson DL, Wagener M: Pneumonia in a long-term care facility: a prospective study of outcome. Arch Intern Med 1996, 156:2365-2370.
33. Delegau J, Guay D, Straub K, Luxenberg MG: Effectiveness of oral antibiotic treatment in nursing home-acquired pneumonia. J Am Geriatr Soc 1995, 43:245-251.
34. Peterson PK, Stein D, Guay DRP: Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. Am J Med 1988, 85:164-171.
35. Almirall J, Mesalles A, Klamburg J, Parra O, Agudo A: Prognostic factors of pneumonia requiring admission to the intensive care unit Chest 1995, 107:511-516.
36. Torres A, Serra-Batlles J, Ferrer A, Jimenez P: Severe community-acquired pneumonia: epidemiologic and prognostic factors. Am Rev Respir Dis 1991, 144:312-318.
37. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P: Severe community-acquired pneumonia: etiology, epidemiology, and prognosis factors. Chest 1994, 105:1487-1495.
38. Kauppinen MT, Herva E, Kujula P: The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneunoniae epidemic in Finland. J Infect Dis 1995, 172:1330-1335.
39. San Pedro GS, Campbell GD Jr: Limitations of diagnostic testing in the initial management of patients with community-acquired pneumonia. Sem Respir Infect 1997, 12:300-307.
40. Ortqvist A, Valtonen M, Cars O, Wahl M: Oral empirc treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996, 110:1499-1506. In a double-blind, multicenter, randomized trial, oral sparfloxacin was superior to roxithromycin (a macrolide antibiotic) as therapy for mild to moderate CAP (favorable responses in 94% and 79%, respectively, of evaluable patients). Clinical successes were achieved with oral sparfloxacin in 25 to 26 (96%) pneumonias due to S. pneumoniae (including seven of eight bacteremias) and in 26 of 27 (96%) cases of CAP due to M. pneumoniae or C. pneumoniae. Roxithromycin was ineffective in all eight patients with pneumonia due to H. influenzae.
41. Ruiz-Gonzales A, Nogues A, Falguera M, Porcel JM, Guelin E, Rubio-Cabellero M: Rapid detection of pneumococcal antigen in lung aspirates: comparison with culture and PCR technique. Respir Med 1997, 91:201-206.
42. Boman J, Allard A, Perssoon K, Lundborg M, Juto P, Wadell G: Rapid diagnosis of respiratory chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA. J Infect Dis 1997, 175:1523-1526.
43. Kashuba AD, Ballow CH: Legioniella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Diagn Microbiol Infect Dis 1996, 24:129-139.
44. Chalasani NP, Valdecanas MA, Gopal AK, McGowan JE Jr, Jurado RL: Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying rists. Chest 1995, 108:932-936.
45. Rahav G, Toledano Y, Engelhard D, Simhon A, Moses AE, Sacks T, Shapiro M: Invasive pneumococcal infections: a comparison between adults and children. Medicine 1997, 76:295-303.
46. Hoffman J, Cetron MS, Farley MM, Baughman WS: The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995, 333:481-486.
47. Pallares R, Linares J, Vadillo M, Cabellos C: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480.
48. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center National Surveillance Study. Antimicrob Agents Chemother 1996, 40:1208-1213. Surveillance data from the Centers for Disease Control and Prevention of 30 medical centers across the United States from 1994 to 1995 delineating levels of resistance among S. pneumoniae to a variety of antibiotics. Correlations between penicillin-resistance and resistance to other classes of antibiotics (eg, cephalosporins, macrolides, and trimethoprim-sulfamethoxazole) were noted.
49. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y, The Laboratory Investigator Group: Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in the 1996-97 respiratory season: the TRUST study. Diag Microbiol Infections 1997, 29:249-257. Prospective study of isolates of community-acquired respiratory pathogens (eg, S. pneumoniae, H. influenzae, and M. catarrhalis) from 434 medical centers from 45 states in 1997. The authors cite an overall incidence of penicillin-resistance among S. pneumoniae of 33% (including 13% high-grade resistance). Also notes correlations between penicillin-resistance and resistance to marcolides and trimethoprim-sulfamethoxazole.
50. Butler JC, Hofman J, Cetron MS, Elliott JA: The continued emergence of drug-resistant pneumococcal infections in the United States. J Infect Dis 1996, 174:986-993.
51. Appelbaum PC: Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1996, 15:932-939.
52. Schuchat A, Robinson K, Wenger JD, Harrison LH: Bacterial meningitis in the United States in 1995. N Engl J Med 1997, 337:970-976.
53. Ednie LM, Visalli MA, Jacobs MR, Appelbaum PC: Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother 1996, 40:1950-1952.
54. Moreno S, Carcia-Leoni ME, Cercenado E, Diaz MD: Infections caused by erythromycin resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995, 20:1195-1200.
55. Fairchok MP, Ashton WS, Fischer GW. Carriage of penicillin-resistant pneumococci in a military population in Washington, D.C.: risk factors and correlation with correlation with clinical isolates. Clin Infect Dis 1996, 22:966-972.
56. Friedland IR, McCracken GJ Jr: Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994, 331:377-382.
57. Clavo-Sanchez AAJ, Giron-Gonzalez JA, Lopez-Prieto D, Canueto-Quintero J: Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997, 24:1052-1059.
58. Olsson-Liljequist B, Hoffman BM, Hedlund J: Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden. Eur J Clin Microbiol Infect 1996, 15:671-675.
59. Brueggemann AB, Kugler KC, Doern CV: In vitro activity of BAY 12-8039, a novel 8-methoxyquniolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997, 41:1594-1597.
60. Goa KL, Bryson HM, Markha A: Sparfloxacin: a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997, 53:700-725.
61. Topkis S, Swarz H, Breish AS, Maroli AN: Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. Clin Ther 1997, 19:975-988.
62. Wagstaff AJ, Balfour JA: Grepfloxacin. Drugs 1997, 53:817-884.
63. Baquero F, Canton R: In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother 1996, suppl A:1-18.
64. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A: A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacln versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agent Chemother 1997, 41:1965-1972. A recent multicenter trial randomly assigned patients with CAP to levofloxacin (500 mg once daily) or comparators (eg, ceftriaxone 1-2 gm once or twice daily) and/or oral cefuroxime axetil (500 mg twice daily). Erythromycin or doxycycline could be added to the comparator arm at the investigator's discretion. Clinical success (cure or improvement) after 5 to 7 days of therapy was superior for the levofloxacin group (96%) compared to the ceftriaxone or cefuroxime axetil group (90%). Levofloxacin was superior to the cephalosporins in microbiologically evaluable patients (clinical success rates of 98% and 88%, respectively). Favorable responses were noted in all 39 patients with CAP due to S. pneumoniae treated with levofloxacin (including nine with bacteremias).
65. Stein GE: Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996, 23(suppl 1):S19-S24.
66. Acar JF, Goldstein FW: Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997, 24(suppl 1):S67-S73.
67. Gold HS, Moellering RC Jr: Antimicrobial drug resistance. N Engl J Med 1996, 335:1445-1453.
68. Chenoweth C, Lynch JP III: Antimicrobial resistance: implications for managing respiratory infections. Curr Opin Pulm Med 1997, 3:159-169.
69. Kauppinen MT, Saikku P, Kujala P, Herva E, Syrjala H: Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996, 51:185-189.
70. Edelstein PH: Antimicrobial chemotherapy for Legionnaire's disease: a review. Clin Infect Dis 1995, 21(suppl 3):S265-S276.
71. Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH: A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990, 161:618-625.
72. Plouffe JF, Breiman RF, Facklam RR: Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA 1996, 275:194-198.
73. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N: Chlamydia pneumoniae: risk factors of seropositivity and association with coronary artery disease. J Infect 1995, 30:121-128.
74. Blasi F, Costentini R, Raccanelli R, Massari FM: A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 1997, 112:309-312.
75. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ: Elevated Chlamydia pneumoniae antibiotics, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997, 96:404-407.
76. Lieberman D, Kahane S, Lieberman D, Friedman MG: Pneumonia with serological evidence of acute infection with the chlymadia-like microorganism "Z". Am J Resp Crit Care Med 1997, 156:578-582.
77. Straus WL, Plouffe JF, File TM Jr, Lipman HB: Risk factors for domestic acquisition of Legionnaire's disease. Arch Intern Med 1996, 156:1685-1692.
78. El-Ebiary M, Sarmiento X, Torres A, Nogue S, Mesalles E, Bodi M, Almirall J: Prognostic factors of severe Legionella pneumonia requiring admission to ICU. Am J Respir Crit Care Med 1997, 156:1467-1472.
79. Pedro-Botet ML, Sbria-Leal M, Haro M, Rubio C, Gimenez G, Sopena N, Tor J: Nosocomial and community-acquired Legionella pneumoniae: clinical comparative analysis. Eur Respir J 1995, 8:1929-1933.
80. Marston BJ, Lipman HB, Breiman RF: Surveillance for Legionnaire's disease: risk factors for morbidity and mortality. Arch Intern Med 1994, 154:2417-2422.
81. Plouffe JF, File TM Jr, Breiman RF, Hackman BA: Re-evaluation of the definition of Legionnaire's disease: use of the urine antigen assay. Clin Infect Dis 1995, 20:1286-1291.
82. Charles L, Segreti J: Choosing the right macrolide antibiotic: a guide to selection. Drugs 1997, 53:349-357.
83. Ehrenkranz NJ, Nerenberg DE, Shultz JM, Slater KC: Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol 1992, 13:21-32.
84. Niederman MS: Hospitalized patients with community-acquired pneumonia: overview of ATS guidelines and initial management Infect Dis Clin Pract 1996, 5(4 suppl):S142-S147.
85. British Thoracic Society: Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993, 49:346-350.
86. Bartlett JG, Breiman RF, Mandell LA, File TM: Community acquired pneumonia in adults: guidelines for management Clin Infect Dis 1998, in press.
87. Gialdroni Grassi G, Bianchi L: Guidelines for the management of community-acquired pneumonia in adults. Monaldi Arch Dis Chest 1995, 50:21-27.
88. Mandell LA, Niederman MS: The Canadian Hospital Acquired Pneumonia Consensus Group: initial antimicrobial treatment of hospital-acquired pneumonia in adults: a conference report Can J Infect Dis 1993, 4:317-321.
89. Woodhead M: Community-acquired pneumonia guidelines: an international comparison. A view from Europe. Chest 1998, 113:183S-187S.
90. Niederman MS: Community-acquired pneumonia: a North American perspective. Chest 1998, 113:179S-182S.
91. Vergis EN, Yu VL: Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. Sem Respir Infect 1997, 12:322-328.
92. Bartlett JG: Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Sem Respir Infect 1997, 12:329-333.
93. Chodosh S, Lakshminarayan S, Swarz H, Breisch S: Efficacy and safety of a 10-day course of 400 to 600 milligrams of grepafloxacin once daily for treatment of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrib Agents Chemother 1998, 42:114-120.
94. Edelstein PH, Edelstein MAC, Ren J, Ptzer R, Gladue RP: Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophilia pneumonia. Antimicrob Agents Chemother 1996, 40:314-319.
95. Klugman KP, Gootz TD: In vitro and in vivo activity of trovafloxacin against Streptococcus pneumonia. J Antimicrobal Chemother 1997, 39(suppl B):51-55.
96. O'Doherty B, Dutchman DA, Pettit R, Maroli A: Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997, 40(suppl A):73-82.
97. Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, Marrie TJ, Coley CM, Walsh MB, Karpf M, Lahive KC, Kapoor WN: The hospital admission decision for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997, 157:36-44. Data from the Pneumonia Patient Outcomes Research Team (PORT) study, which examined the determinants of the discharge decision in patients treated for CAP. The results suggest potential routes to improve treatment decisions.
98. Gilbert K, Gleason PP, Singer DE, Marrie TJ, et al.: Variations in antimicrobial use and cost in more than 2,000 patients with community acquired pneumonia. Am J Med 1998, 104:17-27. The authors assessed route, dose, duration of administration, and costs of antimicrobials prescribed for 972 outpatients and 1328 inpatients enrolled in the Pneumonia Patient Outcomes Research Team (PORT) multicenter, prospective study. Medical outcomes were no worse at institutions with the lowest antimicrobial costs. Differences in antimicrobial prescribing patterns were explained in part by institutional differences in antimicrobial formulary restrictions that limited the use of expensive antibiotics. Formulary restrictions may reduce health care costs without negatively impacting outcomes.
99. Guest JF, Morris A: Community acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997, 10:1530-1534.
100. Porath A, Schlaeffer F, Lieberman D: Appropriateness of hospitalization of patients with community-acquired pneumonia. Ann Emerg Med 1996, 27:176-183.
101. Weingarten S, Riedinger M, Varsi G, Hoah M, Belman M, Meyer R, Ellrodt G: Identification of low-risk hospitalized patients with pneumonia. Chest 1994, 105:1109-1115.
102. Rhew DC, Hackner D, Henderson L, Ellrodt AG, Weingarten SR: The clinical benefit of in-hospital observation in "low-risk" pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 1998, 113:142-146. Retrospective review of 717 consecutive adult patients hospitalized for CAP. Of 144 patients classified as "low risk," 102 patients were observed in the hospital after converting to oral antibiotics (switch therapy) and 40 were discharged after switch to oral antibiotics. No patient from either group required medical intervention within 24 hours of hospital discharge. No patient from either group died. The practice of observing patients with CAP in the hospital after converting to oral antibiotics is not necessary and increases costs.
103. Weingarten SR, Riedinger MS, Hobson P, Noah MS, Johnson B, Giugliano G, Norian J, Belman MJ, Ellrodt AG: Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med 1996, 153:1110-1115. Prospective trial confirming the value of a multidisciplinary practice guideline in achieving early switch therapy and expedited hospital discharge with preserved patient outcomes.
104. Nathwanni D: Sequential switch therapy for lower respiratory tract Infections: a European perspective. Chest 1998, 113:211S-218S.
105. Van den Brande P, Vongra V, Vogel F, et al.: Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest 1997, 112:406-415.
106. Paladino JA, Sperry HE, Backes J: Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991, 91:462-470.
107. Sanders WE, Morris JF, Alessi PK, Makris AT: Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with usual care in a multicenter clinical trial. Am J Med 1991, 91:261-266.